These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38103962)

  • 1. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Cernuschi T; Malvolti S; Hall S; Debruyne L; Bak Pedersen H; Rees H; Cooke E
    Vaccine; 2024 Apr; 42 Suppl 1(Suppl 1):S64-S72. PubMed ID: 38103962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution.
    Agampodi S; Mogeni OD; Chandler R; Pansuriya M; Kim JH; Excler JL
    Expert Rev Vaccines; 2024; 23(1):761-772. PubMed ID: 39167221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Kumar Suri R; Hayman B; Prasad SD; Makhoana M; Tippoo P
    Vaccine; 2022 Jun; 40(26):3495-3505. PubMed ID: 35577632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risky business: COVAX and the financialization of global vaccine equity.
    Stein F
    Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors, enablers and challenges for COVID-19 vaccine development.
    Excler JL; Saville M; Privor-Dumm L; Gilbert S; Hotez PJ; Thompson D; Abdool-Karim S; Kim JH
    BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37277195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating Hurdles: A Review of the Obstacles Facing the Development of the Pandemic Treaty.
    Sheerah HA; Alzaaqi SM; Arafa A; AlSalamah S; Muriungi NG; Sampaio BFC; Tromp J; Liu K; Shirai K; Withers M; Al-Jedai A
    J Epidemiol Glob Health; 2024 Sep; 14(3):580-585. PubMed ID: 38683485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study.
    Barnsley G; Olivera Mesa D; Hogan AB; Winskill P; Torkelson AA; Walker DG; Ghani AC; Watson OJ
    Lancet Glob Health; 2024 Nov; 12(11):e1764-e1774. PubMed ID: 39424569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financing pandemic prevention, preparedness and response: lessons learned and perspectives for future.
    Ndembi N; Dereje N; Nonvignon J; Aragaw M; Raji T; Fallah MP; Abdulaziz M; Djoudalbaye B; Aluso A; Boum Ii Y; Mwaba G; Shisana O; Ngongo N; Kaseya J
    Global Health; 2024 Aug; 20(1):65. PubMed ID: 39169389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead.
    Massinga Loembé M; Nkengasong JN
    Immunity; 2021 Jul; 54(7):1353-1362. PubMed ID: 34260880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities to accelerate immunization progress in middle-income countries.
    Zhu J; Cole CB; Fihman J; Adjagba A; Dasic M; Cernuschi T
    Vaccine; 2024 Apr; 42 Suppl 1():S98-S106. PubMed ID: 37460357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access considerations for a COVID-19 vaccine for South Africa.
    Bangalee V; Suleman F
    S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do we change our approach to COVID with the changing face of disease?
    Apostolopoulos V; Feehan J; Chavda VP
    Expert Rev Anti Infect Ther; 2024 May; 22(5):279-287. PubMed ID: 38642067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring future perspectives and pipeline progression in vaccine research and development.
    Vecchio R; Gentile L; Tafuri S; Costantino C; Odone A
    Ann Ig; 2024; 36(4):446-461. PubMed ID: 38436081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries.
    Parray AA; Yadav UN; Das A; Ali AM; Mollick S; Saha S; Mistry SK
    Glob Public Health; 2022 Apr; 17(4):614-621. PubMed ID: 35050840
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Pagliusi S; Hayman B; Jarrett S
    Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.